

The Catapults

- Part of a world-leading network of technology and innovation centres
- **Bridge the gap** between businesses, academia, research and government
- Access technical facilities and expertise to help adopt, develop and exploit innovations
- Established by Innovate UK

The Cell and Gene Therapy Catapult mission:



Growing the UK cell and gene therapy industry, delivering health and wealth.



Leading edge capabilities and unique assets





Development Facility

- 1200m2 purpose built centre
- Analytical characterisation and process development
- Viral vector
- Collaboration space

Large scale manufacturing development centre

- 7,200m2 manufacturing centre designed specifically for cell and gene therapies
- 12 Unique supported modules
- Located in the Stevenage Biocatalyst
- Currently being commissioned



Leading edge capabilities and unique assets





Cell and gene therapy specialists

- Process Industrialisation
- Health Economics and Reimbursement
- Regulatory
- Non clinical safety
- Clinical
- Manufacturing and Supply Chain
- Programme Management
- Support Services



How we work

£ Core

Key challenges and barriers
A unique technical capability
Industry & research
advisory groups
Demonstration projects
Disseminate to industry

£ Commercial

Access to unique facilities & expertise

Develop & demonstrate at scale

Reduce risk of implementation

Direct contracts for projects

Easy access for SMEs

£ CR&D

Innovation in collaborations

Bring together customers, SME's & blue-chip companies


Technical & management resource

Partners in Projects (IUK & EU)

Expertise at unlocking funding



Our projects



Carried out or committed



Our collaborations



Collaborations



Projects

We work with the owners of promising technologies to accelerate their development into investible products.





Harvest T-cells

Genetically engineer to modify specificity



T-cell receptor therapy



Infuse back into patient



Anti-tumour activity



Collaborations

01

Projects

We work with the owners of promising technologies to accelerate their development into investible products.

02

Platforms

Identifying and tackling industry issues and creating technological innovation.





Collaborations

01

Projects

We work with the owners of promising technologies to accelerate their development into investible products.

02

Platforms

Identifying and tackling industry issues and creating technological innovation.

03

Environment shaping

Creating an advantageous environment in the UK for developers and manufacturers.





Industry growth

£35m+

Investment attracted by UK companies 2012

22

ATMP developers in 2012

540

jobs in 2012

21

clinical trials in 2012

11

GMP facilities in 2012 totalling 5,900m²

To March 17

£355m

Raised by CGT Catapult collaborators

64

ATMP developers in 2017 and rapidly growing

+1,000

jobs in 2015 with more expected in 2017

59

clinical trials in 2017

23

GMP facilities in 2017, with the CGT Catapult manufacturing centre providing an extra 7200²

